Although some adverse effects were observed in a dose-dependent manner, treatment was able to decrease sweat chloride concentration and improve ppFEV1 in CF patients carrying G551D-CFTR in at least one allele (Davies et al., 2019a). The gene discussed is CFTR; the disease is cystic fibrosis.